List of Tables
Summary Table: Global Biosimilars Market, by Region, Through 2029
Table 1: Differences Between Generic and Biosimilar Drugs
Table 2: Terminology Related to Biosimilars
Table 3: Biosimilars Vs. Biobetters
Table 4: Examples of Approved Biobetters
Table 5: Representative Biobetters in Clinical Trials
Table 6: Key Developments in Biosimilar Recombinant Hormones
Table 7: Key Developments in Biosimilar Recombinant Growth Factors
Table 8: Key Developments in Biosimilar Monoclonal Antibodies
Table 9: Key Developments in Enbrel (Etanercept) Biosimilars
Table 10: Key Developments in Biosimilar Interferons
Table 11: Key Developments in LMWHs Biosimilars
Table 12: Global Biosimilars Market, by Product Type, Through 2029
Table 13: EMA Approved Biosimilar Monoclonal Antibodies
Table 14: FDA Approved Biosimilar Monoclonal Antibodies
Table 15: Global Biosimilar Monoclonal Antibodies Market, by Region, Through 2029
Table 16: Global Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 17: Global Trastuzumab Biosimilars Market, by Region, Through 2029
Table 18: Global Rituximab Biosimilars Market, by Region, Through 2029
Table 19: Global Adalimumab Biosimilars Market, by Region, Through 2029
Table 20: Global Bevacizumab Biosimilars Market, by Region, Through 2029
Table 21: Global Infliximab Biosimilars Market, by Region, Through 2029
Table 22: EMA Approved Recombinant Growth Factors Biosimilars
Table 23: FDA Approved Recombinant Growth Factors Biosimilars
Table 24: Global Recombinant Growth Factors Biosimilars Market, by Region, Through 2029
Table 25: Global Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 26: Global Filgrastim Biosimilars Market, by Region, Through 2029
Table 27: Global Epoetin Alfa Biosimilars Market, by Region, Through 2029
Table 28: Global Pegfilgrastim Biosimilars Market, by Region, Through 2029
Table 29: EMA Approved Recombinant Hormones Biosimilars
Table 30: FDA Approved Recombinant Hormones Biosimilars
Table 31: Global Recombinant Hormones Biosimilars Market, by Region, Through 2029
Table 32: Global Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 33: Global Insulin Biosimilars Market, by Region, Through 2029
Table 34: Global Somatotropin Biosimilars Market, by Region, Through 2029
Table 35: Global Teriparatide Biosimilars Market, by Region, Through 2029
Table 36: Global Follitropin Alfa Biosimilars Market, by Region, Through 2029
Table 37: Global Fusion Protein Biosimilars Market, by Region, Through 2029
Table 38: Global Other Biosimilars Market, by Region, Through 2029
Table 39: Global Biosimilars Market, by Therapeutic Application, Through 2029
Table 40: Global Cancer and Related Disorders Market in Biosimilars, by Region, Through 2029
Table 41: Global Autoimmune and Inflammatory Diseases Market in Biosimilars, by Region, Through 2029
Table 42: Global Diabetes Market in Biosimilars, by Region, Through 2029
Table 43: Global Anemia Market in Biosimilars, by Region, Through 2029
Table 44: Global Growth Hormone Deficiency Market in Biosimilars, by Region, Through 2029
Table 45: Global Other Diseases Market in Biosimilars, by Region, Through 2029
Table 46: Global Biosimilars Market, by Region, Through 2029
Table 47: North American Biosimilars Market, by Country, Through 2029
Table 48: North American Biosimilars Market, by Product Type, Through 2029
Table 49: North American Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 50: North American Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 51: North American Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 52: North American Biosimilars Market, by Therapeutic Application, Through 2029
Table 53: Biosimilar Approvals in the U.S.
Table 54: U.S. Biosimilars Market, by Product Type, Through 2029
Table 55: U.S. Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 56: U.S. Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 57: U.S. Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 58: U.S. Biosimilars Market, by Therapeutic Application, Through 2029
Table 59: Canadian Biosimilars Market, by Product Type, Through 2029
Table 60: Canadian Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 61: Canadian Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 62: Canadian Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 63: Canadian Biosimilars Market, by Therapeutic Application, Through 2029
Table 64: Mexican Biosimilars Market, by Product Type, Through 2029
Table 65: Mexican Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 66: Mexican Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 67: Mexican Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 68: Mexican Biosimilars Market, by Therapeutic Application, Through 2029
Table 69: Biosimilar Approvals in Europe
Table 70: European Biosimilars Market, by Country, Through 2029
Table 71: European Biosimilars Market, by Product Type, Through 2029
Table 72: European Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 73: European Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 74: European Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 75: European Biosimilars Market, by Therapeutic Application, Through 2029
Table 76: German Biosimilars Market, by Product Type, Through 2029
Table 77: German Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 78: German Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 79: German Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 80: German Biosimilars Market, by Therapeutic Application, Through 2029
Table 81: U.K. Biosimilars Market, by Product Type, Through 2029
Table 82: U.K. Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 83: U.K. Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 84: U.K. Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 85: U.K. Biosimilars Market, by Therapeutic Application, Through 2029
Table 86: French Biosimilars Market, by Product Type, Through 2029
Table 87: French Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 88: French Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 89: French Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 90: French Biosimilars Market, by Therapeutic Application, Through 2029
Table 91: Italian Biosimilars Market, by Product Type, Through 2029
Table 92: Italian Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 93: Italian Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 94: Italian Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 95: Italian Biosimilars Market, by Therapeutic Application, Through 2029
Table 96: Spanish Biosimilars Market, by Product Type, Through 2029
Table 97: Spanish Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 98: Spanish Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 99: Spanish Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 100: Spanish Biosimilars Market, by Therapeutic Application, Through 2029
Table 101: Rest of European Biosimilars Market, by Product Type, Through 2029
Table 102: Rest of European Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 103: Rest of European Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 104: Rest of European Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 105: Rest of European Biosimilars Market, by Therapeutic Application, Through 2029
Table 106: Asia-Pacific Biosimilars Market, by Country, Through 2029
Table 107: Asia-Pacific Biosimilars Market, by Product Type, Through 2029
Table 108: Asia-Pacific Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 109: Asia-Pacific Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 110: Asia-Pacific Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 111: Asia-Pacific Biosimilars Market, by Therapeutic Application, Through 2029
Table 112: Biosimilar Approvals in China
Table 113: Chinese Biosimilars Market, by Product Type, Through 2029
Table 114: Chinese Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 115: Chinese Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 116: Chinese Recombinant Hormones Biosimilars, by Product Type, Through 2029
Table 117: Chinese Biosimilars Market, by Therapeutic Application, Through 2029
Table 118: Japanese Biosimilars Market, by Product Type, Through 2029
Table 119: Japanese Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 120: Japanese Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 121: Japanese Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 122: Japanese Biosimilars Market, by Therapeutic Application, Through 2029
Table 123: Indian Biosimilars Market, by Product Type, Through 2029
Table 124: Indian Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 125: Indian Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 126: Indian Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 127: Indian Biosimilars Market, by Therapeutic Application, Through 2029
Table 128: Australian Biosimilars Market, by Product Type, Through 2029
Table 129: Australian Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 130: Australian Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 131: Australian Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 132: Australian Biosimilars Market, by Therapeutic Application, Through 2029
Table 133: South Korean Biosimilars Market, by Product Type, Through 2029
Table 134: South Korean Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 135: South Korean Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 136: South Korean Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 137: South Korean Biosimilars Market, by Therapeutic Application, Through 2029
Table 138: Rest of Asia-Pacific Biosimilars Market, by Product Type, Through 2029
Table 139: Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 140: Rest of Asia-Pacific Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 141: Rest of Asia-Pacific Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 142: Rest of Asia-Pacific Biosimilars Market, by Therapeutic Application, Through 2029
Table 143: RoW Biosimilars Market, by Product Type, Through 2029
Table 144: RoW Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 145: RoW Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 146: RoW Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 147: RoW Biosimilars Market, by Therapeutic Application, Through 2029
Table 148: Select Strategic Alliances in the Biosimilars Industry, 2022-2024
Table 149: Leading Biosimilars Companies, by Revenue, 2023
Table 150: U.S. Patent Expirations and Biosimilars, 2024
Table 151: Pending Biosimilar Patent Litigation, 2024
Table 152: FDA Guidelines on Biosimilars, February 2021
Table 153: Biosimilar Products Approved in China, 2024
Table 154: Key Focus Areas in ESG Metrics
Table 155: ESG Rankings for Key Players in Biosimilars Market, 2024*
Table 156: Information Sources in This Report
Table 157: Glossary of Terms Used in the Biosimilars Market
Table 158: Accord BioPharma Inc.: Company Snapshot
Table 159: Accord BioPharma Inc.: Product Portfolio
Table 160: Accord BioPharma Inc.: News/Key Developments, 2024
Table 161: Alvotech: Company Snapshot
Table 162: Alvotech: Financial Performance, FY 2022 and 2023
Table 163: Alvotech: Product Portfolio
Table 164: Alvotech: News/Key Developments, 2024
Table 165: Amgen Inc.: Company Snapshot
Table 166: Amgen Inc.: Financial Performance, FY 2022 and 2023
Table 167: Amgen Inc.: Product Portfolio
Table 168: Amgen Inc.: News/Key Developments, 2022-2023
Table 169: Amneal Pharmaceuticals LLC.: Company Snapshot
Table 170: Amneal Pharmaceuticals LLC.: Financial Performance, FY 2022 and 2023
Table 171: Amneal Pharmaceuticals LLC.: Product Portfolio
Table 172: Amneal Pharmaceuticals LLC.: News/Key Developments, 2023-2024
Table 173: Biocon Biologics Ltd.: Company Snapshot
Table 174: Biocon Biologics Ltd.: Financial Performance, FY 2022 and 2023
Table 175: Biocon Biologics Ltd.: Product Portfolio
Table 176: Biocon Biologics Ltd.: News/Key Developments, 2022-2024
Table 177: Biogen: Company Snapshot
Table 178: Biogen: Financial Performance, FY 2022 and 2023
Table 179: Biogen: Product Portfolio
Table 180: Biogen: News/Key Developments, 2023-2024
Table 181: Celltrion Inc.: Company Snapshot
Table 182: Celltrion Inc.: Financial Performance, FY 2022 and 2023
Table 183: Celltrion Inc.: Product Portfolio
Table 184: Celltrion Inc.: News/Key Developments, 2023-2024
Table 185: Coherus BioSciences: Company Snapshot
Table 186: Coherus BioSciences: Financial Performance, FY 2022 and 2023
Table 187: Coherus BioSciences: Product Portfolio
Table 188: Coherus BioSciences: News/Key Developments, 2024
Table 189: Fresenius Kabi AG: Company Snapshot
Table 190: Fresenius Kabi AG: Financial Performance, FY 2022 and 2023
Table 191: Fresenius Kabi AG: Product Portfolio
Table 192: Fresenius Kabi AG: News/Key Developments, 2024
Table 193: Lilly: Company Snapshot
Table 194: Lilly: Financial Performance, FY 2022 and 2023
Table 195: Lilly: Product Portfolio
Table 196: Lilly: News/Key Developments, 2022-2023
Table 197: Pfizer Inc.: Company Snapshot
Table 198: Pfizer Inc.: Financial Performance, FY 2022 and 2023
Table 199: Pfizer Inc.: Product Portfolio
Table 200: Pfizer Inc.: News/Key Developments, 2023
Table 201: Samsung Bioepis: Company Snapshot
Table 202: Samsung Bioepis: Product Portfolio
Table 203: Samsung Bioepis: News/Key Developments, 2023-2024
Table 204: Sandoz Group AG: Company Snapshot
Table 205: Sandoz Group AG: Financial Performance, FY 2022 and 2023
Table 206: Sandoz Group AG: Product Portfolio
Table 207: Sandoz Group AG: News/Key Developments, 2024
Table 208: Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 209: Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2022 and 2023
Table 210: Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 211: Teva Pharmaceutical Industries Ltd.: News/Key Developments, 2023-2024
Table 212: Viatris Inc.: Company Snapshot
Table 213: Viatris Inc.: Financial Performance, FY 2022 and 2023
Table 214: Viatris Inc.: Product Portfolio
Table 215: Viatris Inc.: News/Key Developments, 2022
List of Figures
Summary Figure: Share of Global Market for Biosimilars, by Region, 2023
Figure 1: Snapshot of the Market Dynamics for Biosimilars
Figure 2: Share of Global Market for Biosimilars, by Product Type, 2023
Figure 3: Global Biosimilar Monoclonal Antibodies Market, by Region, 2021-2029
Figure 4: Global Recombinant Growth Factors Biosimilars Market, by Region, 2021-2029
Figure 5: Global Recombinant Hormones Biosimilars Market, by Region, 2021-2029
Figure 6: Global Fusion Protein Biosimilars Market, by Region, 2021-2029
Figure 7: Global Other Biosimilars Market, by Region, 2021-2029
Figure 8: Share of Global Market for Biosimilars, by Therapeutic Application, 2023
Figure 9: Global Cancer and Related Disorders Market in Biosimilars, 2021-2029
Figure 10: Global Cancer and Related Disorders Market in Biosimilars, by Region, 2021-2029
Figure 11: Global Autoimmune and Inflammatory Diseases Market in Biosimilars, 2021-2029
Figure 12: Global Autoimmune and Inflammatory Diseases Market in Biosimilars, by Region, 2021-2029
Figure 13: Global Diabetes Market in Biosimilars, 2021-2029
Figure 14: Global Diabetes Market in Biosimilars, by Region, 2021-2029
Figure 15: Global Anemia Market in Biosimilars, 2021-2029
Figure 16: Global Anemia Market in Biosimilars, by Region, 2021-2029
Figure 17: Global Growth Hormone Deficiency Market in Biosimilars, 2021-2029
Figure 18: Global Growth Hormone Deficiency Market in Biosimilars, by Region, 2021-2029
Figure 19: Global Other Diseases Market in Biosimilars, 2021-2029
Figure 20: Global Other Diseases Market in Biosimilars, by Region, 2021-2029
Figure 21: Share of Global Market for Biosimilars, by Region, 2023
Figure 22: Global Biosimilars Market, by Region, 2021-2029
Figure 23: Share of North American Market for Biosimilars, by Country, 2023
Figure 24: U.S. Biosimilars Market, 2021-2029
Figure 25: Canadian Biosimilars Market, 2021-2029
Figure 26: Mexican Biosimilars Market, 2021-2029
Figure 27: Share of European Market for Biosimilars, by Country, 2023
Figure 28: German Biosimilars Market, 2021-2029
Figure 29: U.K. Biosimilars Market, 2021-2029
Figure 30: French Biosimilars Market, 2021-2029
Figure 31: Italian Biosimilars Market, 2021-2029
Figure 32: Spanish Biosimilars Market, 2021-2029
Figure 33: Rest of European Biosimilars Market, 2021-2029
Figure 34: Share of Asia-Pacific Market for Biosimilars, by Country, 2023
Figure 35: Chinese Biosimilars Market, 2021-2029
Figure 36: Japanese Biosimilars Market, 2021-2029
Figure 37: Indian Biosimilars Market, 2021-2029
Figure 38: Australian Biosimilars Market, 2021-2029
Figure 39: South Korean Biosimilars Market, 2021-2029
Figure 40: Rest of Asia-Pacific Biosimilars Market, 2021-2029
Figure 41: Snapshot of the ESG Pillars
Figure 42: Advantages of ESG for Biosimilar Companies
Figure 43: Share of Biotech Companies Providing ESG Disclosure, 2022
Figure 44: Share of ESG Disclosure, by Location, 2022
Figure 45: Alvotech: Revenue Share, by Country/Region, FY 2023
Figure 46: Amgen Inc.: Revenue Share, by Country/Region, FY 2023
Figure 47: Amneal Pharmaceuticals LLC.: Revenue Share, by Business Unit, FY 2023
Figure 48: Biocon Biologics Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 49: Biocon Biologics Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 50: Biogen: Revenue Share, by Business Unit, FY 2023
Figure 51: Biogen: Revenue Share, by Country/Region, FY 2023
Figure 52: Fresenius Kabi AG: Revenue Share, by Business Unit, FY 2023
Figure 53: Lilly: Revenue Share, by Business Unit, FY 2023
Figure 54: Lilly: Revenue Share, by Country/Region, FY 2023
Figure 55: Pfizer Inc.: Revenue Share, by Business Unit, FY 2023
Figure 56: Pfizer Inc.: Revenue Share, by Country/Region, FY 2023
Figure 57: Sandoz Group AG: Revenue Share, by Business Unit, FY 2023
Figure 58: Sandoz Group AG: Revenue Share, by Country/Region, FY 2023
Figure 59: Teva Pharmaceutical Industries Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 60: Viatris Inc.: Revenue Share, by Business Unit, FY 2023
Figure 61: Viatris Inc.: Revenue Share, by Country/Region, FY 2023